However, there are not yet any approved therapies that follow Opko’s modality of simultaneously activating the GLP-1 and glucagon receptors. Big Pharmas have tended to evaluate dual GLP-1 ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon. It has ...

Liraglutide is a peptide that has gained significant attention in scientific research due to its structural similarity to glucagon-like peptide-1 (GLP-1). Studies suggest that this peptide may ...